Oral Microbiome Richness Tied to CRS - Scorecard - MDSpire

Oral Microbiome Richness Tied to CRS

A cross-sectional metagenomic study found greater oral microbiome richness among adults with chronic rhinosinusitis, particularly nonallergic chronic rhinosinusitis, while associations with asthma, airway inflammation, and most lung-function measures were inconsistent.

  • By

  • Andrea Surnit

  • July 8, 2026

  • 4 min

Share

Clinical Scorecard: Oral Microbiome Richness Tied to CRS

At a Glance

CategoryDetail
ConditionChronic Rhinosinusitis (CRS)
Key MechanismsAssociation between oral microbiome richness and chronic rhinosinusitis prevalence.
Target PopulationAdults from the European Community Respiratory Health Survey.
Care SettingRespiratory health research.

Key Highlights

  • Increased oral microbiome richness linked to chronic rhinosinusitis.
  • Strongest association observed in nonallergic chronic rhinosinusitis.
  • No consistent association found between alpha diversity and asthma.
  • Functional gene profiling revealed differences based on respiratory outcomes.
  • Study limitations include cross-sectional design and potential misclassification.

Guideline-Based Recommendations

Diagnosis

  • Chronic rhinosinusitis defined by symptoms lasting more than 12 weeks.

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Participants from Bergen, Norway; Tartu, Estonia; and Melbourne, Australia.

        No specific treatment insights provided.

        Clinical Best Practices

        • Consider oral microbiome richness in assessing chronic rhinosinusitis.

        Related Resources & Content

        Original Source(s)

        Oral Microbiome Richness Tied to CRS

        • by Andrea Surnit

        • July 8, 2026

        Related Content

        Efficacy and safety of Tuina therapy for children with combined allergic rhinitis and asthma syndrome in remission: a randomized controlled trial protocol

        FDA Expands Afrezza to Pediatric Diabetes

        The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

        Effects of metabolic syndrome on pulmonary infection in pediatric bronchial asthma: a narrative review